Raymond James & Associates’s PAVmed Inc. Series Z Warrant PAVMZ Stock Holding History

Raymond James & Associates’s Portfolio PAVMZ Stock Details PAVMZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-174,542	Closed	-$27.9K	–	3958
2023 Q2	$27.9K	Sell	174,542 -160,994	-48%	-$20.8K	﹤0.01%	3753
2023 Q1	$50.3K	Sell	335,536 -400	-0.1%	-$79	﹤0.01%	3731
2022 Q4	$73.9K	Buy	+335,936	New	+$139K	﹤0.01%	3683
2021 Q2	–	Sell	-389,353	Closed	-$1.1M	–	4235
2021 Q1	$1.1M	Buy	+389,353	New	+$784K	﹤0.01%	2439

Other funds holding PAVMZ

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Raymond James & Associates's PAVMZ Position: Q3 2023 in Review

Raymond James & Associates sold out of PAVmed Inc. Series Z Warrant (PAVMZ) in Q3 2023, closing a stake of 174,542 shares — an estimated $27.9K sold.

Raymond James & Associates first reported a position in PAVMZ in Q1 2021 and held it in 4 quarters. The position peaked at $1.1M in Q1 2021. 4 funds tracked by Wall St. Rank hold PAVMZ as of Q3 2023.

Raymond James & Associates reported no remaining PAVmed Inc. Series Z Warrant position as of Q3 2023 after selling out during the quarter.
Raymond James & Associates sold 174,542 PAVmed Inc. Series Z Warrant shares in Q3 2023, an estimated $27.9K.
Raymond James & Associates first reported a position in PAVmed Inc. Series Z Warrant in Q1 2021 and held it in 4 quarters.
Raymond James & Associates's PAVmed Inc. Series Z Warrant position peaked at $1.1M in Q1 2021.
4 funds tracked by Wall St. Rank held PAVmed Inc. Series Z Warrant as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.